Not Yet RecruitingPhase 1

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canada30 participantsStarted 2026-05-01

Plain-language summary

Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Who can participate

Age range15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Progressive disease following at least one line of systemic treatment for metastatic disease which must include an ADC (all participants) and an ICI (participants whose tumours express PD-L1).
✓. ≤3 lines of treatment for metastatic disease.
✓. Must have had at least 1 prior line of cytotoxic chemotherapy for breast cancer, in any setting, which must have included an anthracycline and a taxane (unless contraindicated).

What they're measuring

To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapy

Timeframe: 3 years

Trial details

NCT IDNCT07297667

SponsorCanadian Cancer Trials Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2028-12-01

Contact for this trial

Laura Pearce

613-533-6430 lpearce@ctg.queensu.ca

View on ClinicalTrials.gov More Alveolar Soft Part Sarcoma trials